FIG 2.
Chalice analysis of ribavirin and INX-08189 combination treatment of the NGC replicon. Luciferase activity was measured at 48 h posttreatment, with a dosing matrix centered on the EC50 of each compound for the Huh-7 NGC replicon. (A) Dose matrix-response values for the combination, showing inhibition of luciferase activity (1 − treated value/untreated value) for the serially diluted compounds. Inhibition values were analyzed by Chalice software to generate the combinations' excess values (the Loewe excess values are shown here). (B) Computed Bliss and HSA excesses for the compound combination. Values are averages for six experiments. (C) Isobologram, synergy score, and best combination index (CI) at 90% inhibition for ribavirin and INX-08189. Values shown are averages for eight experiments. (D) Cell viability with drug combination treatment. The concentrations of ribavirin and INX-08189 were identical to those used in the dose matrix for antiviral activity assay (see panel A). The synergy calculation was derived from averages for eight data sets.